MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

5.870 +0.740 (+14.42%)
Streaming Delayed Price Updated: 1:06 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split ↗
Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2,... 
Via Stocktwits
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track ↗
Via Stocktwits
News headline image
MicroMarvel - Atossa Therapeutics ↗
Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals 
Via Talk Markets
News headline image
Why Did ATOS Stock Jump 10% In Pre-Market Today? ↗
The U.S. Food and Drug Administration granted Orphan Drug Designation to its (Z)-Endoxifen therapy for DMD. 
Via Stocktwits
News headline image
Why Are Shares Of Atossa Therapeutics Up Today? ↗
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know. 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
Via ACCESS Newswire
News headline image
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Earnings Scheduled For March 25, 2025 ↗
 
Via Benzinga
News headline image
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024 ↗
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace
News headline image
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 ↗
If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today. 
Via InvestorPlace
News headline image
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
News headline image
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off ↗
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
News headline image
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 ↗
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar ↗
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. 
Via InvestorPlace
News headline image
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 ↗
ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market ↗
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
News headline image
This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm" ↗
Dr. Steven Quay MD, PhD, President & CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga. 
Via Benzinga
News headline image
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via ACCESSWIRE
News headline image
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment ↗
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst ↗
Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story